TP-317 is a first-in-class small molecule oral therapy in development for ulcerative colitis and Crohn’s Disease RIDGEFIELD, CT – (January 20, 2021) – Thetis Pharmaceuticals (“Thetis”), a biopharmaceutical company developing novel therapies for autoimmune and inflammatory disorders, announced today that it completed a Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration […]

Thetis’ drug candidate TP-317 is a first-in-class small molecule oral therapy in development for inflammatory bowel disease (IBD) RIDGEFIELD, CT – (December 14, 2020) – Thetis Pharmaceuticals (“Thetis”), a biopharmaceutical company developing novel therapies for autoimmune and inflammatory disorders, announced today that it has received U.S. Food and Drug Administration orphan drug designation for TP-317 […]

TP-317 is a first-in-class small molecule oral therapy in development for ulcerative colitis and Crohn’s Disease RIDGEFIELD, CT – (July 23, 2020) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on developing Resolvin-based therapies for inflammatory diseases, announced today that the European Patent Office has granted patent EP 3157936 providing composition of matter protection […]

Thetis CEO, Gary Mathias, presents on Non-immunosuppressive Therapies for Gastrointestinal Diseases BRANFORD, CT – (February 17, 2020) – Thetis Pharmaceuticals, a biopharmaceutical company developing non-immunosuppressive lipid therapies for treatment of gastrointestinal (GI) diseases, announced that its CEO, Gary Mathias, will present at NobleCon16 – Noble Capital Markets’ Sixteenth Annual Investor Conference at the Hard Rock […]